MED2002 Clinical Trial Update

RNS Number : 9098F

Futura Medical PLC

17 November 2015

 



For immediate release

17 November 2015

Futura Medical plc

("Futura" or the "Company")

MED2002 Clinical Trial Update

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces the following update on progress of its pivotal efficacy study of MED2002, the Company's novel gel for the treatment of erectile dysfunction ("ED").

Recruitment of patients for the study is proceeding well, with 118 patients having enrolled in the study to date.  Once enrolled, the clinical test period per patient is approximately three months. A total of 192 patients are expected to take part in the trial, which remains on track to deliver headline results by the end of H1 2016.

All of the patients recruited to date have been enrolled in London and, as previously advised, further recruitment sites within the EU have been identified. Ethics approvals for these sites have now been obtained and pending regulatory approval overseas recruitment is expected to commence in the New Year.

No serious adverse events have been recorded to date among the patients who have participated in the trial, which is of a randomised, placebo-controlled, double blind, home use, crossover design. Because the trial is blinded, efficacy data will not be available until the end of the trial.

The primary endpoint of the study is the efficacy of MED2002 in male subjects self-diagnosed with ED using the erectile function domain of the International Index of Erectile Function (IIEF). The IIEF is a well validated measure of erectile function and was used for the approval of PDE5 inhibitors, such as Viagra®. Secondary endpoints in the trial include the speed of onset.

James Barder, Futura's Chief Executive, commented: "We are pleased by the pace of recruitment to this pivotal trial of MED2002 in erectile dysfunction. MED2002 is a novel, topical gel with potential benefits including the speed of onset of action and the use of the product as part of sexual foreplay. The current trial is focused on demonstrating efficacy and remains on track to deliver headline results by the end of the first half next year."

For further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
Email to: [e-mail]	www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Liz Yong / Tom Smale Corporate Finance	Tel:[phone]
For media enquiries please contact:
Buchanan
Mark Court / Sophie Cowles / Stephanie Watson	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

About MED2002

MED2002 is the development name for Futura Medical's medicinal treatment for men with erectile dysfunction ("ED"). Futura holds worldwide rights to MED2002, which contains the active ingredient glyceryl tri-nitrate.

A clinical study of MED2002 is currently under way in more than 192 patients with ED. The primary outcome of the study, which is of a randomised, placebo-controlled, double blind, home use, crossover design, is statistically significant efficacy. The clinical trial is expected to report before the end of H1, 2016.

In the most recent data published by the NHS spending on drugs to treat ED in General Practice in England exceeded £80 million per annum¹.

¹  http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PPDPrescribingAnalysisCharts/Endocrine_National_Mar_12.pdf

 

END

 

 

MSCFMMMMNVRGKZM